IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attv. Ref.: 620-347

Group: 1645

Examiner: Unassigned

In re Patent Application of

Filed: November 30, 2004

For: METHODS OF PURIFICATION OF CYTOCHROME P450 PROTEINS AND OF THEIR CRYSTALLIZING

COSME ET AL Serial No. 10/516,338

Commissioner for Patents July 26, 2006 P.O. Box 1450 Alexandria, VA 22313-1450			
Sir:		INFORMATION DISCLOSURE STATEMENT	
\boxtimes	1.	PTO-1449 Pursuant to 37 CFR 1.97(b) [within 3 months of filing or prior to 1st Office Action on	the merits]
	2.(a)	Statement Pursuant to 37 CFR 1.97(c) [before Final Office Action or Allowance (requires Rule Statement <u>or</u> Rule 17(p) fee)]	97(e) N/C
	2 .(b)	Fee Payment Pursuant to 37 CFR 1.97(c) [before Final Office Action or Allowance (requires Rule Statement or Rule 17(p) fee)]	97(e) \$180.00
	3.	Pursuant to 37 CFR 1.97(d) [after Final Office Action or Allowance (requires Rule 9 Statement and Rule 17(p) fee), but before final fee pay	

The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98: X 4. A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith This paper is submitted in accordance with: 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action] П 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]: and The required Statement made in item 8 below; or □ b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below. 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith: and The required Statement is stated in item 8 below. □ 8. Statement under 37 CFR 1.97(e) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS): or □ b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart

Disclosure Statement

foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR \$1.56(c) more than three months prior to the filing of this Information Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

> Respectfully submitted, NIXON & VANDERHYE P.C.

NIXON & VANDERHYE P.C.

By: /B. J. Sadoff/
B. J. Sadoff
Reg. No. 36,663

901 North Glebe Road, 11th Floor Arlington, VA 22203-1808 Telephone: (703) 816-4000 Facsimile: (703) 816-4100 Sheet 1 of 1 ATTY: DOCKET NO. SERIAL NO. INFORMATION DISCLOSURE CITATION 620-347 10/516 338 APPLICANT COSME ET AL (Use several sheets if necessary) EILING DATE GROUE 1645 November 30, 2004 U.S. PATENT DOCUMENTS DOCUMENT NUMBER DATE MARKE CHBCLACE IE ADDRODRIATE FOREIGN PATENT DOCUMENTS TRANSLATION DOCUMENT DATE COUNTRY CLASS SUBCLASS YES NO OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.) 1 Boddupalli et al, Proc. Natl. Acad. Sci., 1992, Vol. 89, pp 5567-5571 2 Obavashi et al. Journal of Inorganic Biochemistry 82 (2000) 103-111 3 Ost et al. Biochemistry 2001, 40, 13430-13438

4 Ost et al. J. Am. Chem. Soc. 2003, 125, 15010-15020 5 Li et al. Acta Cryst. (1995). D51, 21-32

6 Poulos, The Journal of Biological Chemistry, 1982, Vol. 257, No. 17. 10427-10429

7 Raag et al. Biochemistry 1991, 30, 11420-11429

8 Hishiki et al. J. Biochem. 2000. 128. 965-974 9 Vidakovic et al. Biochemistry, 1998, Vol. 37, No. 26, pp 9211-9219

*Examiner Date Considered Examiner: Initial if reference considered, whether or not obtains is nonformance with MPEP 509; Drawline through obtains if not in conformance and not considered. Inc copy of this form with next communication to application

Form PTO-FR-4820 (Also PTO-1449)